The Ensign Group, Inc.
ENSG
$172.99
+3.27%
The Ensign Group, Inc. provides post-acute healthcare services in the United States, operating skilled nursing, assisted living, home health, hospice, mobile ancillary, and urgent care facilities. As a leading operator in the fragmented skilled nursing industry, Ensign differentiates itself through a decentralized regional operating model and a captive REIT structure (Standard Bearer) that provides real estate ownership and leasing flexibility. The current investor narrative centers on Ensign's consistent revenue growth driven by demographic tailwinds and acquisition-led expansion, while margin improvement and operational efficiency remain key focal points amid Medicare/Medicaid reimbursement dynamics.…
ENSG
The Ensign Group, Inc.
$172.99
ENSG 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on The Ensign Group, Inc.'s 12-month outlook, with a consensus price target around $217.80 and implied upside of +25.9% versus the current price.
Average Target
$217.80
0 analysts
Implied Upside
+25.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$202 - $230
Analyst target range
Ensign Group is covered by 5 analysts, with a consensus recommendation of 'Buy' (mean score 1.6 on a 1-5 scale, where 1 is Strong Buy). The average target price is $217.80, implying approximately 27% upside from the current price of $171.28. The distribution shows no sell ratings, with a mix of Buy and Hold ratings, reflecting a bullish consensus. The target range spans from $202.00 (low) to $230.00 (high), indicating a spread of $28.00 or 13% of the average target. The high target of $230 assumes continued strong execution, margin expansion, and successful acquisitions, while the low target of $202 may factor in potential reimbursement headwinds or slower growth. Recent ratings from Truist Securities (Hold), RBC Capital (Outperform), and UBS (Buy) show a stable outlook with no recent downgrades. The relatively narrow spread suggests moderate conviction among analysts, and the implied upside supports a positive investment thesis.
Bulls vs Bears: ENSG Investment Factors
Ensign Group presents a compelling growth story with accelerating revenue, expanding margins, and strong free cash flow, supported by demographic tailwinds and a fragmented market. The bull case is anchored by 18.4% revenue growth, improving profitability, and 27% analyst upside. However, the bear case highlights a trailing P/E near historical highs, recent price weakness, and elevated debt. The key tension is whether the company can sustain its growth trajectory to justify the premium valuation. Currently, the bull case has stronger evidence given consistent execution and forward P/E compression, but the stock's recent underperformance warrants caution. The single most important factor is whether Ensign can maintain revenue growth above 15% and expand margins, which would validate the current multiple and drive the stock toward analyst targets.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 18.4% YoY to $1.389 billion, accelerating from 8.5% in Q2 2025, driven by acquisitions and organic occupancy gains. This outpaces the industry average of ~10%, signaling strong execution and market share gains.
- Expanding Profit Margins: Net margin improved to 7.2% in Q1 2026 from 6.8% a year ago, while operating margin expanded to 9.0% from 8.6%. This demonstrates operational leverage and cost control, supporting earnings growth.
- Strong Free Cash Flow Generation: TTM free cash flow stands at $406.1 million, yielding ~4.1% on the current market cap. This provides ample liquidity for acquisitions and organic investments without relying on external financing.
- Analyst Consensus and Upside: With 5 analysts covering, the consensus is Buy (mean 1.6/5) and the average target price of $217.80 implies 27% upside from $171.28. No sell ratings and a narrow target range ($202-$230) indicate moderate conviction in the growth story.
Bearish
- Elevated Valuation on Trailing Basis: Trailing P/E of 29.0x is near the top of its historical range (17.5x-29.6x) and at a 32% premium to the sector median of ~22x. This leaves little room for error if growth disappoints.
- Recent Price Decline and Momentum Loss: The stock is down 21% from its 52-week high of $218 and has underperformed the S&P 500 by 19.1% over the past 3 months. The 6-month price change is -5.1%, indicating persistent selling pressure.
- High Debt-to-Equity Ratio: Debt-to-equity of 1.86 is elevated, reflecting the REIT structure and acquisition financing. While manageable, it increases financial risk if interest rates remain high or cash flows weaken.
- Reimbursement and Regulatory Risk: Medicare and Medicaid programs contribute the majority of revenue. Changes in reimbursement rates or policies could pressure margins. The industry is subject to frequent regulatory audits and compliance costs.
ENSG Technical Analysis
Ensign Group's stock has experienced a volatile year, with a 1-year price change of +23.4%, but the current price of $171.28 sits at 55% of its 52-week range ($134.79–$218.00), indicating a significant pullback from the highs. The stock is trading well below its 52-week high of $218, suggesting a loss of momentum and potential value territory, though the proximity to the 52-week low of $134.79 offers a support level. The 1-year relative strength against SPY is +5.0%, but the 3-month relative strength is -19.1%, highlighting underperformance in the recent quarter. Short-term momentum shows a sharp divergence: the 1-month price change is +9.9%, a strong recovery from the 3-month decline of -14.4%. This recent bounce suggests a potential short-term reversal or mean reversion, but the 6-month change of -5.1% indicates lingering weakness. The beta of 0.69 implies the stock is less volatile than the market, which may appeal to risk-averse investors but also limits upside during market rallies. The 52-week low of $134.79 serves as critical support; a break below could signal further downside, while a move above the 52-week high of $218 would indicate a resumption of the long-term uptrend. The current price is 21% above the 52-week low, providing a buffer, but the stock remains 21% below the high, reflecting the recent correction.
Beta
0.69
0.69x market volatility
Max Drawdown
-31.8%
Largest decline past year
52-Week Range
$142-$218
Price range past year
Annual Return
+25.6%
Cumulative gain past year
| Period | ENSG Return | S&P 500 |
|---|---|---|
| 1m | +5.4% | +0.8% |
| 3m | -8.5% | +3.5% |
| 6m | -1.4% | +7.2% |
| 1y | +25.6% | +16.5% |
| ytd | -0.5% | +8.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ENSG Fundamental Analysis
Ensign's revenue trajectory remains robust, with Q1 2026 revenue of $1.389 billion, up 18.4% year-over-year, accelerating from the 8.5% growth in Q2 2025. The Skilled Services segment generated $1.331 billion in Q1 2026, representing 96% of total revenue, while the Standard Bearer segment contributed $36.1 million. This consistent double-digit growth is driven by acquisitions and organic occupancy improvements, reinforcing the investment case for continued expansion. Profitability is solid, with Q1 2026 net income of $99.7 million and a net margin of 7.2%, up from 6.8% in the year-ago quarter. Gross margin improved to 16.4% from 16.0% in Q1 2025, while operating margin expanded to 9.0% from 8.6%, indicating operational leverage. The company is consistently profitable, with trailing twelve-month net income of $363.4 million, and margins are trending upward, which is favorable for the investment thesis. Ensign maintains a healthy balance sheet with a current ratio of 1.42 and generates strong free cash flow of $406.1 million (TTM), providing ample liquidity for acquisitions and organic investments. The debt-to-equity ratio of 1.86 is elevated but manageable given the REIT structure, and ROE stands at 15.4%, reflecting efficient capital use. Free cash flow yield is approximately 4.1% based on the current market cap, supporting internal funding of growth initiatives.
Quarterly Revenue
$1.4B
2026-03
Revenue YoY Growth
+18.4%
YoY Comparison
Gross Margin
16.4%
Latest Quarter
Free Cash Flow
$406100000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ENSG Overvalued?
Given Ensign's positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 29.0x, while the forward P/E is 20.6x, implying the market expects significant earnings growth over the next year. The gap between trailing and forward P/E suggests strong growth expectations, which aligns with the company's historical performance. Compared to the industry average (Medical Care Facilities), Ensign trades at a premium. The trailing P/E of 29.0x is above the sector median of roughly 22x, representing a 32% premium. This premium is justified by Ensign's superior revenue growth (18.4% YoY vs. industry average of ~10%) and expanding margins, as well as its market leadership in skilled nursing. Historically, Ensign's trailing P/E has ranged from 17.5x (mid-2022) to 29.6x (Q3 2025). The current 29.0x is near the top of its historical band, indicating that the market is pricing in optimistic growth expectations. While this could signal overvaluation, the forward P/E of 20.6x suggests that earnings growth will bring the multiple down, making the stock appear more reasonably priced on a forward basis.
PE
29.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 17x~30x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
24.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Ensign's debt-to-equity ratio of 1.86 is elevated, reflecting its REIT structure and acquisition strategy. While interest coverage is adequate (EBITDA of $159.3M vs. interest expense of $1.9M in Q1 2026), rising interest rates could increase borrowing costs. The company's net margin of 7.2% is modest, leaving limited buffer against cost inflation or reimbursement cuts. Revenue concentration in skilled services (96% of total) exposes the company to segment-specific headwinds. Free cash flow of $406.1M TTM provides a cushion, but any disruption in cash generation could strain the acquisition pipeline.
Market & Competitive Risks: The stock's trailing P/E of 29.0x is at a 32% premium to the sector median, making it vulnerable to multiple compression if growth slows. With a beta of 0.69, the stock is less correlated to the market, but its 3-month relative strength of -19.1% indicates sector rotation or company-specific concerns. The skilled nursing industry is highly competitive and fragmented, with pricing pressure from managed care organizations. Regulatory changes, such as Medicaid reimbursement adjustments, could impact profitability. No recent news highlights immediate threats, but the industry faces ongoing scrutiny over quality of care.
Worst-Case Scenario: A combination of slower revenue growth (e.g., below 10%), margin compression from wage inflation or reimbursement cuts, and a de-rating of the P/E multiple to the historical low of 17.5x could drive the stock to $134.79 (52-week low) or lower. This represents a potential 21% downside from the current price of $171.28. If the company faces a major regulatory setback or acquisition integration failure, the stock could test the $130 level, implying a 24% loss. The max drawdown of -31.83% from the 52-week high suggests that severe corrections are possible.